Medicines Australia will be appointing a new chair. To what extent does it matter? The participation model means that the industry might be effectively shackled to the 'change' table rather than having a seat at it. The government has worked it out, constantly increasing the price of participation and limiting exclusionary discussions about change. How does that need to change?
